Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.6.1.2 (alanine aminotransferase)
 26,722 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A phase II study of bronchial artery infusion of mitomycin C (MMC) was performed in 14 patients with non-small cell lung cancer (6 patients with adenocarcinoma, 6 patients with squamous cell carcinoma and 2 patients with large cell carcinoma). MMC at a dose of 20 mg was infused into the bronchial artery (total dose 20-60 mg, mean 27 mg). Among the 14 patients, one with adenocarcinoma of the lung showed partial response. The response rate for bronchial artery infusion of MMC was thus 7.1%. The toxic effects included anemia (35.7%), leukopenia (28.6%), thrombopenia (14.3%), elevation of GPT (14.3%), anorexia (14.3%), nausea (7.1%) and eruption (7.1%).
 ...
PMID:[Phase II study of bronchial artery infusion of mitomycin C in non-small cell lung cancer]. 302 79

CB3717 is a quinazoline antifolate whose cytotoxic activity is mediated by inhibition of thymidylate synthase (TS). A phase I clinical trial commenced in September 1981 and 99 patients have received 296 treatments. Doses were dissolved in 0.15 mol/L NaHCO3 (pH 9.0) at a concentration of 4 mg/mL infused over one hour or in a total volume of 1 L infused over 12 hours. Doses were repeated every 3 weeks. The starting dose of 140 mg/m2 was escalated to 600 mg/m2. Renal toxicity, detected by a decrease in the 51Cr EDTA clearance, was dose-related and occurred in seven of ten patients receiving greater than 450 mg/m2. Reversible hepatic toxicity often associated with malaise occurred in 223 of 288 assessable courses (77%). Fifty-nine courses (20%) were associated with increases in alanine transaminase (ALT) levels to greater than 2.5 times the upper limit of the normal laboratory range. Increases in alkaline phosphatase levels also occurred, but were less marked. The severity and prevalence of these elevations were unaffected by the duration of the infusion. A self-limiting rash appeared in 12 patients and a radiation recall reaction was seen in two. Leukopenia developed in 17 patients (WBC less than 3 X 10(9)/L), and thrombocytopenia occurred in six patients (platelets less than 100 X 10(9)/L). The mean leucocyte nadir occurred on day 10 and was followed by recovery at 11 to 19 days. Neither the incidence nor the severity of any of these latter toxicities was dose related. The maximum tolerated dose was in the region of 600 mg/m2 with renal toxicity being dose limiting, although the inter-patient variation did not allow a precise definition. Seventy-six patients were evaluable for response. Responses occurred at doses greater than or equal to 200 mg/m2 and were ovary, one complete response (CR), one partial response (PR), seven minor responses (MR) in 30 cases; breast, two PRs and one MR in eight cases; adenocarcinoma of the lung, one MR in 5 cases; mesothelioma, one PR in five cases; and colon, two MRs in four cases. CB3717 has activity in heavily pretreated patients. The recommended phase II dose for good-risk patients is 400 mg/m2 using the one-hour infusion schedule of administration.
 ...
PMID:A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717. 373 49

Forty-one cases of adenocarcinoma of the lung with pleuritis carcinomatosa were randomly assigned to either chemotherapy alone or chemoimmunotherapy using Nocardia rubra cell wall skeleton as immunopotentiator. In 34 evaluable patients, the rates of volume decrease and the disappearance of tumor cells in pleural effusion were higher in chemoimmunotherapy group than in chemotherapy alone group, and median survival times from the beginning of treatment in chemotherapy alone and chemoimmunotherapy groups were 189 and 266 days, respectively. The survival times in patients with stage III and P.S. 0+1+2 were better than those in patients with stage IV and P.S. 3, respectively. Transient fever and mild elevation of GPT and GOT were tolerated without any treatment.
 ...
PMID:[Effect of Nocardia rubra cell wall skeleton against pleuritis carcinomatosa in adenocarcinoma of the lung]. 688 78

A 79-year-old woman with adenocarcinoma of the lung almost fully obstructing the right main bronchus and with multiple bone and brain metastases was admitted to our hospital in March 2005. Irradiation was considered to be successful. Since subsequent vinorelbine chemotherapy was futile, it was changed to gefitinib in June. A week after gefitinib therapy, serum alkaline phosphatase (ALP) began to increase from about 400 IU/l to 1247 IU/l, to 3470 IU/l after two weeks, and up to 3527 IU/l after three weeks. The levels then decreased to within the normal range after nine weeks. ALP isozyme showed a peak composed of ALP2 and ALP3, and the levels of other enzymes (GOT, GPT, gamma-GTP) were normal. Hence, increased ALP was thought to be derived from the bones. The patient's performance status and metastases improved during this phenomenon. Bone scintigraphy findings one month after beginning gefitinib therapy worsened, but improved after four months. Bone ALP represents osteoblastic activity. We believe that in this case bone formation became dominant because of the favorable response to gefitinib therapy.
 ...
PMID:[A case of lung cancer with alkaline phosphatase flare phenomenon during gefitinib therapy]. 1818 43